A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody

Annals of Hematology

Volumn 82, Issue 12, 2003, Pages 766-768

  Gholam, Dany ^a,b   Vantelon, Jean Marie ^b   Al Jijakli, Ahmad ^b   Bourhis, Jean Henri ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Anti CD20 monoclonal antibody; Multicentric Castleman's disease; Secondary amyloidosis

Indexed keywords

CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; RITUXIMAB; VINBLASTINE;

ADULT; AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANOREXIA; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CELL TYPE; DEATH; DISEASE ASSOCIATION; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE BIOPSY; LYMPHOPROLIFERATIVE DISEASE; PHYSICAL EXAMINATION; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; VIRUS INFECTION;

ADULT; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; MULTIPLE ORGAN FAILURE;

EID: 0347519172     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0718-x     Document Type: Article

References (24)

1. Keller A, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670-683
2. Flendrig J, Schillings PHM (1969) Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 12:119
3. Peterson B, Frizzera G (1993) Multicentric Castleman's disease. Semin Oncol 20:636-647
4. Chronowski G, Ha C, Wilder R et al (2001) Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 92:670-676
5. Katano H, Sata T (1999) An attractive relation of human herpesvirus-8 with multicentric Castleman's disease. Intern Med 38:221-222
6. Hayashi M, Aoshiba K, Shimada M et al (1999) Kaposi's sarcoma-associated herpesvirus infection in the lung in multicentric Castleman's disease. Intern Med 38:279-282
7. Bowne W, Lewis J, Filippa D, et al (1999) The management of unicentric and multicentric Castleman's disease. Cancer 85:706-717
8. Andres E, Maloisel F (2000) Interferon-α as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol 11:1613-1614
9. Rieu P, Droz D, Gessain A et al (1999) Retinoic acid for treatment of multicentric Castleman's disease. Lancet 354:1262-1263
10. Nishimoto N, Sasai M, Shima Y, Nakagawa M et al (2000) Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56-61
11. Corbellino M, Bestetti G, Scalamogna C et al (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 12:3473-3475
12. Suda T, Katano H, Delsol G, Kakiuchi C, Nakamura T et al (2001) HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 51:671-679
13. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M et al (2002) Update on Kaposi's sarcoma and other HHV-8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2:344-352
14. West KP, Morgan DR, Lauder I (1989) Angiofollicular lymph node hyperplasia with amyloidosis. Postgrad Med J 65:108-111
15. Ordi J, Grau JM, Junque A, Nomdeleu B, Palacin A, Cardesa A (1993) Secondary (AA) amyloidosis associated with Castleman's disease. Am J Clin Pathol 100:394-397
16. Miura A, Saro I, Suzuki C (1995) Fatal diarrhea in a patient with Castleman's disease associated with intestinal amyloidosis. Intern Med 34:1106-1109
17. Tanaka K, Horita M, Shibayama H, Seike M, Itoh Y et al (1995) Secondary amyloidosis associated with Castleman's disease. Intern Med 34:122-126
18. Funabiki K, Kaneko S, Terajima M, Tomita H, Kawano Y, Tomino Y (1998) A case of multicentric Castleman's disease associated with renal amyloidosis and pure red cell aplasia. Am J Nephrol 18:247-250
19. Altiparmak MR, Pamuk GE, Pamuk ON, Dogusoy G (2002) Secondary amyloidosis in Castleman's disease: review of the literature and report of a case. Ann Hematol 81:336-339
20. Derici U, Arinsoy T, Ataoglu O, Bali M, Sindel S et al (2002) Localized Castleman's disease and nephrotic syndrome not responsive to resection plus colchicine therapy. Ann Hematol 81:399-401
21. Sezer O, Eucker J, Schmid P, Possinger K (2000) New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol 79:1-6
22. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA (1999) Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 17:262-267
23. Van Eygen K, Zachee P, Maertens J, Vandenberghe P, Demuynck H, Verhoef G, Boogaerts A (1996) Treatment of primary amyloidosis with VAD combination chemotherapy results in improved survival. Blood 88(1):591a
24. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone and melaphalan, prednisone and colchicine. N Engl J Med 336:1202-1207